购物车
- 全部删除
- 您的购物车当前为空
IBL-302 (AMU302) 是一种口服有效的PIM和PI3K/AKT/mTOR双信号抑制剂,具有抗乳腺癌和成神经细胞瘤的活性。在裸鼠异种移植模型中,IBL-302 显示出体内效力,并能抑制曲妥珠单抗的耐药性问题。此外,IBL-302 还能增强顺铂、阿霉素和依托泊苷等常见细胞毒性化疗药物的效果。
IBL-302 (AMU302) 是一种口服有效的PIM和PI3K/AKT/mTOR双信号抑制剂,具有抗乳腺癌和成神经细胞瘤的活性。在裸鼠异种移植模型中,IBL-302 显示出体内效力,并能抑制曲妥珠单抗的耐药性问题。此外,IBL-302 还能增强顺铂、阿霉素和依托泊苷等常见细胞毒性化疗药物的效果。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3]. |
别名 | AMU302 |
分子量 | 567.63 |
分子式 | C25H18FN5O4S3 |
CAS No. | 1414455-21-2 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容